A new report from the free-market policy group Unleash Prosperity highlights that reducing the Food and Drug Administration's (FDA) drug review process by just one year could generate over $10 trillion in economic value and expedite access to lifesaving medicines for patients [1]. The report, titled 'The Multi-Trillion Dollar Opportunity in Reforming the FDA,' emphasizes that the majority of the FDA's approval timeline is consumed by effectiveness reviews rather than safety testing [1]. Economist Tomas Philipson, former acting chairman of the White House Council of Economic Advisers, stated that the entire FDA approval process typically takes about a decade, with most delays attributed to effectiveness trials rather than safety assessments [1].
The report argues that accelerating the approval process would not only benefit patients but also encourage greater investment in medical innovation by providing earlier access to new treatments, biologics, and medical devices [1]. It further suggests that faster approvals could help reduce prescription drug costs by increasing competition among manufacturers [1]. Philipson noted that reforming the FDA would have a significant impact on drug affordability due to enhanced competition from quicker market entry of new drugs [1].
Additionally, the report raises concerns about the United States potentially losing its competitive edge in drug development to China, which offers a faster and lower-cost clinical trial system that could attract investment away from the U.S. [1]. To address these challenges, the authors propose reforms such as greater use of artificial intelligence in drug reviews, faster clinical trial designs, and expanded access to 'right to try' programs [1]. Philipson also called for presidential leadership akin to Operation Warp Speed during COVID-19 to accelerate the approval process for other patient groups [1].
The report questions whether the federal government should maintain its current level of involvement in determining a drug's effectiveness before market entry, suggesting that a reevaluation of this role could further streamline the process [1].
CONCLUSION
The report underscores the significant economic and patient benefits of expediting the FDA's drug approval process, estimating a potential $10 trillion boost from cutting one year off the timeline. Proposed reforms aim to enhance innovation, affordability, and U.S. competitiveness in drug development. The findings suggest that policy changes could have a substantial positive impact on both the healthcare sector and the broader economy.